SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-23-093116
Filing Date
2023-12-05
Accepted
2023-12-05 16:01:11
Documents
13
Period of Report
2023-11-28
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea189533-8ka1_elevailabs.htm   iXBRL 8-K/A 29843
2 COLLABORATION AGREEMENT, DATED NOVEMBER 28, 2023, BY AND BETWEEN THE COMPANY AND ea189533ex10-1_elevailabs.htm EX-10.1 195653
  Complete submission text file 0001213900-23-093116.txt   446576

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE elab-20231128.xsd EX-101.SCH 3030
4 XBRL LABEL FILE elab-20231128_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE elab-20231128_pre.xml EX-101.PRE 22369
7 EXTRACTED XBRL INSTANCE DOCUMENT ea189533-8ka1_elevailabs_htm.xml XML 4311
Mailing Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660
Business Address 120 NEWPORT CENTER DRIVE STE 250 NEWPORT BEACH CA 92660 18667944940
Elevai Labs Inc. (Filer) CIK: 0001840563 (see all company filings)

IRS No.: 851399981 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-41875 | Film No.: 231466481
SIC: 2834 Pharmaceutical Preparations